Atika Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Atika Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.3M	Buy	61,000 +41,875	+219%	+$9.78M	1.07%	25
2026 Q1	$4.37M	Sell	19,125 -1,517	-7%	-$340K	0.55%	47
2025 Q4	$4.4M	Sell	20,642 -1,518	-7%	-$314K	0.46%	60
2025 Q3	$4.41M	Buy	22,160 +5,760	+35%	+$1.07M	0.35%	64
2025 Q2	$2.83M	Sell	16,400 -18,800	-53%	-$3.06M	0.28%	54
2025 Q1	$5.49M	Buy	+35,200	New	+$5.03M	0.77%	41
2024 Q4	–	Sell	-43,000	Closed	-$6.42M	–	90
2024 Q3	$6.42M	Buy	+43,000	New	+$5.81M	0.66%	49
2024 Q2	–	Sell	-48,500	Closed	-$7.33M	–	93
2024 Q1	$7.33M	Buy	+48,500	New	+$6.92M	0.72%	52
2020 Q1	–	Sell	-52,000	Closed	-$7.23M	–	87
2019 Q4	$7.23M	Buy	52,000 +27,000	+108%	+$3M	1.4%	32
2019 Q3	$2.41M	Sell	25,000 -16,000	-39%	-$1.78M	0.51%	58
2019 Q2	$4.72M	Sell	41,000 -5,000	-11%	-$598K	0.93%	47
2019 Q1	$5.41M	Buy	+46,000	New	+$4.03M	1.1%	40
2018 Q3	–	Sell	-15,700	Closed	-$1.04M	–	88
2018 Q2	$1.04M	Buy	+15,700	New	+$1.03M	0.2%	83

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Atika Capital Management's ASND Position: Q2 2026 in Review

Atika Capital Management increased its Ascendis Pharma A/S (ASND) stake by 219% in Q2 2026, buying an estimated $9.78M and bringing the position to 61,000 shares worth $16.3M. The position accounts for 1.07% of the portfolio, ranked #25.

Atika Capital Management first reported a position in ASND in Q2 2018 and has held it in 13 quarters since. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Atika Capital Management held 61,000 shares of Ascendis Pharma A/S worth $16.3M as of Q2 2026.
Atika Capital Management bought 41,875 Ascendis Pharma A/S shares in Q2 2026, an estimated $9.78M.
Ascendis Pharma A/S made up 1.07% of Atika Capital Management's portfolio in Q2 2026, its #25 holding.
Atika Capital Management first reported a position in Ascendis Pharma A/S in Q2 2018 and has held it in 13 quarters since.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Atika Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.